
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-04 08:51:07.252735
  Output will be saved to: test_outputs\workflow_test_20251204_085107.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 43 papers ---
  Full text (PMC): 20
  LLM verified: 43

  Diseases (36):
    - vitiligo: 3
    - atopic dermatitis: 3
    - juvenile idiopathic arthritis: 2
    - adult-onset Still's disease: 2
    - systemic lupus erythematosus: 2
    - multiple inflammatory cutaneous diseases: 1
    - dermatomyositis: 1
    - giant cell arteritis: 1
    - type I interferonopathies: 1
    - non-infectious uveitis: 1
    - folliculitis decalvans: 1
    - SAPHO syndrome: 1
    - polymyalgia rheumatica and giant cell arteritis: 1
    - dystrophic epidermolysis bullosa: 1
    - JIA-associated uveitis: 1

--- Sample Papers ---

  1. Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid...
     PMID: 38853646 | Disease: vitiligo
     Full text: False
     Why: Prospective case series with patient outcomes for vitiligo treatment...

  2. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Dis...
     PMID: 38051858 | Disease: multiple inflammatory cutaneous diseases
     Full text: False
     Why: Case series with 6 patients showing efficacy outcomes in dermatomyositis, hidrad...

  3. JAK inhibitors in refractory dermatomyositis: A case series....
     PMID: 38887110 | Disease: dermatomyositis
     Full text: False
     Why: Retrospective cohort study with 14 patients showing efficacy data including CDAS...

  4. Clinical experience and safety of Janus kinase inhibitors in giant cel...
     PMID: 37304255 | Disease: giant cell arteritis
     Full text: True
     Why: Retrospective case series with 15 patients showing clinical outcomes and inflamm...

  5. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies:...
     PMID: 35418997 | Disease: type I interferonopathies
     Full text: True
     Why: Case series assessing efficacy and safety in type I interferonopathies including...

--- Validation ---
  PASS: Found 43 papers
  WARN: 1 potentially irrelevant papers
    - Pharmacokinetics, Pharmacodynamics, and Proposed D...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 3 papers...
  (2 have PMC full text)

  1. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant Cell Arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors demonstrated significant efficacy in GCA patients with inadequate...
     Safety: Generally well tolerated with only 2 serious infections observed. No cases of ma...

  2. [PMC] Janus Kinase Inhibitors in the Treatment of Type I Inte...
     WARN: No data extracted

  3. [Abstract only] Oral tofacitinib, baricitinib and upadacitinib monother...
     WARN: No data extracted

--- Validation ---
  Successful: 1/3

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 1 extractions...

--- Scored Opportunities ---
